Onconetix, Inc. (ONCO)
NASDAQ: ONCO · Real-Time Price · USD
2.860
-0.040 (-1.38%)
Nov 5, 2024, 3:48 PM EST - Market open
Company Description
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology.
It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023.
Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Onconetix, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Feb 18, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Ralph Schiess |
Contact Details
Address: 201 East Fifth Street, Suite 1900 Cincinnati, Ohio 45202 United States | |
| Phone | 513 620 4101 |
| Website | onconetix.gcs-web.com |
Stock Details
| Ticker Symbol | ONCO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $9.00 |
| CIK Code | 0001782107 |
| CUSIP Number | 682160106 |
| ISIN Number | US09610B1089 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ralph Schiess Ph.D. | Interim Chief Executive Officer and Chief Science Officer |
| Karina M. Fedasz | Interim Chief Financial Officer |
| Dr. Brian Price Ph.D. | Head of Technology Strategy |
| Frank A. Jaeger M.A., M.B.A. | Senior Vice President of Marketing and Business Development |
| Andrew D. Skibo Ph.D. | Global Head of Biologics Operations |
| Theodore Scott Yoho | Head of Business Development |
| Dr. Ali I. Fattom Ph.D. | Head of Science and Discovery |
| Dr. Jay Newmark M.B.A., M.D. | Chief Medical Officer |
| Christian Bruhlmann | Chief Strategy Officer and GM of Europe |
| Dr. Donald L. Very Jr., Ph.D. | Senior Vice President of Commercial Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 1, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Nov 1, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Oct 31, 2024 | DEF 14C | Filing |
| Oct 21, 2024 | 8-K | Current Report |
| Oct 18, 2024 | PRE 14C | Filing |
| Oct 17, 2024 | D | Notice of Exempt Offering of Securities |
| Oct 9, 2024 | 8-K/A | [Amend] Current report |
| Oct 3, 2024 | 8-K | Current Report |
| Oct 1, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Oct 1, 2024 | SC 13D | General statement of acquisition of beneficial ownership |